LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

Search

Erasca Inc

Chiusa

1.21 0.83

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.21

Massimo

1.23

Metriche Chiave

By Trading Economics

Entrata

1.3M

-31M

EPS

-0.11

Dipendenti

103

EBITDA

-750K

-36M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+263.64% upside

Dividendi

By Dow Jones

Utili prossimi

8 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-45M

348M

Apertura precedente

0.38

Chiusura precedente

1.21

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

Erasca Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

23 mag 2025, 20:33 UTC

Acquisizioni, Fusioni, Takeovers

Salesforce in Talks to Buy Informatica, Bloomberg Reports, Citing Sources

24 mag 2025, 08:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

24 mag 2025, 08:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

24 mag 2025, 07:00 UTC

Utili

Retailers Are Giving Mixed Messages on Prices. What Will s Really Happen at Checkout. -- Barrons.com

23 mag 2025, 21:57 UTC

Azioni calde

Stocks to Watch: Apple, Booz Allen, Constellation Energy, Intuit -- WSJ

23 mag 2025, 21:15 UTC

Notizie principali

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 4th Update

23 mag 2025, 21:04 UTC

Acquisizioni, Fusioni, Takeovers

Real-Estate Broker Douglas Elliman Could See Takeover Battle After Report of Bid -- Barrons.com

23 mag 2025, 20:56 UTC

Notizie principali
Acquisizioni, Fusioni, Takeovers

Salesforce Back in Deal Talks With Informatica -- WSJ

23 mag 2025, 20:51 UTC

Notizie principali

Boeing in Tentative Agreement to Pay $1.1 Billion to Avoid Trial for 737 MAX Crashes -- WSJ

23 mag 2025, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

23 mag 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

23 mag 2025, 20:41 UTC

Notizie principali

Stocks Fall on Tariff Broadside, After Week of Bond Market Agita -- WSJ

23 mag 2025, 20:28 UTC

Notizie principali

Trump Threatens EU With 50% Tariffs, Takes Aim at Apple; Nasdaq Drops -- WSJ

23 mag 2025, 20:06 UTC

Notizie principali

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 5th Update

23 mag 2025, 20:06 UTC

Acquisizioni, Fusioni, Takeovers

Salesforce Stock Drops, Informatica Soars. A Deal May Be Back on the Table. -- Barrons.com

23 mag 2025, 19:50 UTC

Notizie principali

Trump's Tariffs: Where Things Stand -- 16th Update

23 mag 2025, 19:28 UTC

Acquisizioni, Fusioni, Takeovers

Trump on Truth Social: 'Bulk of That Investment Will Occur in the Next 14 Months'

23 mag 2025, 19:28 UTC

Acquisizioni, Fusioni, Takeovers

Trump on Truth Social: 'This Will Be a Planned Partnership Between United States Steel and Nippon Steel'

23 mag 2025, 19:27 UTC

Acquisizioni, Fusioni, Takeovers

Trump on Truth Social: 'Proud to Announce That, After Much Consideration and Negotiation, US Steel Will REMAIN in America'

23 mag 2025, 19:20 UTC

Discorsi di Mercato

Crude Futures Post Modest Weekly Losses -- Market Talk

23 mag 2025, 19:18 UTC

Discorsi di Mercato

U.S. Natural Gas Futures End Week Unchanged -- Market Talk

23 mag 2025, 18:57 UTC

Notizie principali

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 4th Update

23 mag 2025, 18:54 UTC

Notizie principali

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- Update

23 mag 2025, 18:53 UTC

Notizie principali
Acquisizioni, Fusioni, Takeovers

McDonald's Bids Goodbye to CosMc's, Its Space Alien-Themed Spinoff -- WSJ

23 mag 2025, 18:52 UTC

Acquisizioni, Fusioni, Takeovers

DDC Enterprise Issues 254,333 Class A Ordinary Shrs in Exchange for 21 BTC, Valued at About $2.28M in Current Market Price

23 mag 2025, 18:13 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

23 mag 2025, 18:13 UTC

Discorsi di Mercato

Gold Trades Higher on Reminder of Risk -- Market Talk

23 mag 2025, 18:00 UTC

Notizie principali

Apple's Stock Still Not Pricing in Trump's Demands - Heard on the Street -- WSJ

23 mag 2025, 17:51 UTC

Discorsi di Mercato
Utili

Workday Sees Higher Bar for Guidance -- Market Talk

23 mag 2025, 17:42 UTC

Notizie principali

Dow Drops, Trump Threatens EU With 50% Tariffs, Takes Aim at Apple -- WSJ

Confronto tra pari

Modifica del prezzo

Erasca Inc Previsione

Obiettivo di Prezzo

By TipRanks

263.64% in crescita

Previsioni per 12 mesi

Media 4.4 USD  263.64%

Alto 6 USD

Basso 3 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Erasca Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

6 ratings

6

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

1.39 / 1.44Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Weak Bearish Evidence

A lungo termine

Very Strong Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.